We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
BACKGROUND In Australia, infliximab (IFX) and adalimumab (ADA) are available for the treatment of moderate-severe Crohn disease (CD) refractory to conventional therapies, with minimal local data comparing their efficacy. AIM The aim of this study was to compare clinical and biochemical outcomes at 3 and 12 months between patients receiving induction and(More)
BACKGROUND The serum soluble cytotoxic T lymphocyte associated antigen-4 (sCTLA-4) concentration is significantly elevated in patients with asthma, and sCTLA-4 concentration correlate with the severity of asthma. The aim of the present study was to investigate effects of allergen inhalation and oral glucocorticoid on concentration of serum sCTLA-4 in(More)
  • 1